MedTrace Logo

Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

NCT02351180 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.

Conditions

  • Lung Transplant Infection

Interventions

DRUG

Inhaled beclomethasone

Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection

DRUG

Placebo

Placebo will serve as a control treatment

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Ramsey Hachem, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2021-01-31
Completion
2021-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02351180 on ClinicalTrials.gov